J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments
Boyu Hu,Keyur P. Patel,Hsiang-Chun Chen,Xuemei Wang,Feng Wang,Rajyalakshmi Luthra,Mark J. Routbort,Rashmi Kanagal-Shamanna,L. J. Medeiros,Cheng C Yin,Zhuang Zuo,Chi Young Ok,Sanam Loghavi,Guilin Tang,Francesco Paolo Tambaro,Philip A. Thompson,Jan A. Burger,Nitin Jain,Alessandra Ferrajoli,Prithviraj Bose,Zeev Estrov,Michael J. Keating,William G. Wierda +22 more
TL;DR: Targeted sequencing of 29 genes previously identified as being mutated in CLL revealed recurrent mutations resulting in premature truncation prior to the ubiquitination domains of NOTCH1 in its PEST domain and BIRC3 in its RING domain can produce proteins that constitutively activate CLL.
Journal ArticleDOI
Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)
Nitin Jain,Michael J. Keating,Philip A. Thompson,Alessandra Ferrajoli,Jan A. Burger,Gautam Borthakur,Koichi Takahashi,Zeev Estrov,Nathan Fowler,Tapan M. Kadia,Marina Konopleva,Yesid Alvarado,Musa Yilmaz,Courtney D. DiNardo,Prithviraj Bose,Maro Ohanian,Naveen Pemmaraju,Elias Jabbour,Koji Sasaki,Rashmi Kanagal-Shamanna,Keyur P. Patel,Jeffrey L. Jorgensen,Naveen Garg,Xuemei Wang,Katrina Sondermann,Nichole Cruz,Chongjuan Wei,Ana Ayala,William Plunkett,Hagop M. Kantarjian,Varsha Gandhi,William G. Wierda +31 more
TL;DR: The firstline cohort of an investigator-initiated phase II trial of combined IBR and VEN for patients with CLL led to downgrading of TLS risk category in 80% of high-risk and 47% of medium-risk pts, and the primary endpoint is CR/CRi.
Journal ArticleDOI
β2-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia
Philip A. Thompson,Susan O'Brien,Lianchun Xiao,Xuemei Wang,Jan A. Burger,Nitin Jain,Alessandra Ferrajoli,Zeev Estrov,Michael J. Keating,William G. Wierda +9 more
TL;DR: A high pretreatment β2‐microglobulin (B2M) level is associated with inferior survival outcomes in patients with chronic lymphocytic leukemia and the prognostic and predictive significance of changes in B2M during treatment have not been reported.
Journal ArticleDOI
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Elias Jabbour,Koji Sasaki,Nicholas J. Short,Farhad Ravandi,Xuelin Huang,Joseph D. Khoury,Rashmi Kanagal-Shamanna,Jeffrey L. Jorgensen,Issa F. Khouri,Partow Kebriaei,Nitin Jain,Yesid Alvarado,Tapan M. Kadia,Shilpa Paul,Guillermo Garcia-Manero,Bouthaina S. Dabaja,Jan A. Burger,Courtney D. DiNardo,Naval A. Daver,Guillermo Montalban-Bravo,Musa Yilmaz,Maro Ohanian,Alessandra Ferrajoli,Jovitta Jacob,Meagan Rostykus,Rebecca Garris,Susan O'Brien,Hagop M. Kantarjian +27 more
TL;DR: The sequential addition of blinatumomab might improve outcome in patients with R/R ALL and the combination of inotuzumab with low‐intensity mini–hyper‐CVD has shown encouraging results.
Journal ArticleDOI
Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients
Michael Andreeff,Zhihong Zeng,Mary A. Kelly,Rui-Yu Wang,Teresa McQueen,Seshagiri Duvvuri,Gul Nowshad,Gautam Borthakur,Jan A. Burger,Tapan M. Kadia,Elias Jabbour,Jorge E. Cortes,Hagop M. Kantarjian,Marina Konopleva +13 more
TL;DR: The combination of G-CSF+Plerixa for appears superior in increasing the number of circulating leukemic blasts and stem/progenitor cells in FLT3-ITD AML, as compared to Plerixafor alone in R/R AML.